Form Type: 4

SEC EDGAR Link
Accession Number:0001140361-21-023007
Date:2021-06-28
Issuer: BROOKLYN IMMUNOTHERAPEUTICS, INC. (BTX)
Original Submission Date:

Reporting Person:

DAMOUR KEVIN
C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
140 58TH STREET, BUILDING A, SUITE 2100 BROOKLYN, NY 11220

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION 21.35 2021-06-28 deemed execution date A 140,580 (a) 2031-06-28 common stock 140,580 $21.35 140,580 direct
RESTRICTED STOCK UNIT 0.0 2021-06-28 deemed execution date A 70,290 (a) 2031-06-28 common stock 70,290 $0.00 70,290 direct
Footnotes
IDfootnote
f1 the option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on june 28, 2022, and 1/36 of the remaining shares covered thereby vesting on the 28th day of each calendar month from july 28, 2022 through june 28, 2025, subject to continued service through each vesting date.
f2 each restricted stock unit represents a contingent right to receive one share of common stock.
f3 the restricted stock unit vests and becomes exercisable in four equal installments on june 28 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a change in control (as defined in dr. d'amour's executive employment agreement, dated as of june 5, 2021 and effective as of june 28, 2021), subject to continued service through each vesting date.

Elevate your investments